Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer.

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer.
Read the original article

Tags:

Previous Article

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of App...

Next Article

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Feb 6, 2024

FDA denies approval for Theratechnologies’ tesamorelin F8

FDA denies approval for Theratechnologies’ tesamorelin F8

Jan 25, 2024

UK Spring Budget allocates funds to life sciences manufacturing

UK Spring Budget allocates funds to life sciences manuf...

Mar 5, 2024